首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1736511

2026 年至 2032 年伊波拉病毒疫苗市场（按病毒株、通路、最终用户和地区划分）

Ebola Virus Vaccine Market By Virus Strain, Distribution Channel, End User, & Region for 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格

简介目录

伊波拉病毒疫苗市场评估 - 2026-2032

伊波拉病毒疫苗全球盛行率上升推动市场成长伊波拉病毒疫苗市场在 2024 年的价值为 1,143 万美元，预计到 2032 年将成长到 9,176 万美元，复合年增长率为 32.80%。

成长轨迹显示市场动态呈上升趋势。预测扩张显示预测期内成长率强劲，2026年至2032年的复合年增长率为32.80%。

伊波拉病毒疫苗市场定义/概述

伊波拉，俗称伊波拉出血热，是伊波拉病毒属的致命病毒性疾病。近年来，伊波拉已成为人类的重大威胁。该病毒通常透过动物传播给人。

伊波拉出血热热是世界上最致命的凝血疾病之一，最常发生在非洲国家。此病是由出血热病毒引起，凝血功能障碍会导致血液从体内小血管漏出，进而引发内出血。伊波拉出血热是由伊波拉属病毒感染引起的。

伊波拉病毒疾病 (EVD) 是一种由伊波拉病毒引起的一种严重且可能致命的人类疾病。伊波拉疫苗市场显着成长，尤其是在2014-2016年西非爆发严重的伊波拉出血热疫情之后，凸显了对有效疫苗的迫切需求，以控制集体爆发并保护民众。

伊波拉疫苗市场是全球防治未来伊波拉出血热疫情的关键组成部分。政府、製药公司、学术机构和非营利组织之间的合作正在推动伊波拉疫苗的研发、生产能力和全球分销。市场挑战包括确保疫苗的可负担性和可近性（尤其是在低收入国家）、解决疫苗犹豫和虚假资讯问题，以及维持长期的生产和供应网络。

全球伊波拉疫苗市场是什么样的？

根据美国国家医学图书馆记载，伊波拉出血热疫情始于1976年。当时，疫情袭击了苏丹南部和刚果民主共和国北部，从6月持续到9月，持续了约四个月，死亡率分别为53%和88.1%。后来被认定为导致最初疫情爆发的两种病毒是伊波拉病毒和萨伊伊波拉病毒。

伊波拉疫苗市场的成长与发展。首要任务是应对伊波拉出血热疫情引发的公共卫生危机。伊波拉病毒疾病 (EVD) 对人体的毁灭性影响及其广泛传播的可能性凸显了采取有效预防措施的必要性。

伊波拉疫苗市场的扩张和发展将使伊波拉疫苗成为全球卫生安全努力的重要组成部分。科学、金融、监管和地缘政治等多种力量共同推动伊波拉疫苗市场的扩张和发展。

伊波拉疫苗市场面临哪些挑战？

目前对伊波拉疫苗的需求主要源于疫情应对，因为疫情的不可预测性以及疾病集中在卫生资源有限的中低收入国家等变数阻碍了大规模疫苗接种计划的实施。

疫苗的研发和生产成本高昂，这可能导致疫苗价格高昂，并限制资源贫乏、疫情最容易发生的地区的疫苗供应和可近性。

物流挑战包括在基础设施匮乏的偏远地区分发和储存疫苗，以及在供应链中维持这些疫苗接种所需的低温运输条件，这增加了新的复杂性。

伊波拉病毒疫苗的严格监管授权可能会严重阻碍市场扩张。监管要求可能会推迟新疫苗的上市，并阻碍新业务进入市场。疫苗研发和商业化的核准时间和成本的增加可能会限制市场成长。资源有限的小型企业可能难以遵守严格的法规，这些法规要求疫苗必须进行全面的临床试验、安全评估和生产。监管壁垒可能会阻碍伊波拉病毒疫苗的商业化和供应，从而阻碍市场成长。

Ebola is one of the world's most deadly diseases caused by blood coagulation. It most typically occurs in African countries. It is characterized as a haemorrhagic fever virus because of the coagulation issues that lead to internal bleeding when blood pours from small blood vessels in the body. It is caused by an infection with viruses from the Ebolavirus genus.

Ebola virus disease (EVD) is a serious and frequently fatal sickness in humans caused by the Ebola virus. The market for Ebola vaccines has grown significantly, particularly after the serious Ebola outbreak in West Africa from 2014 to 2016, which emphasized the critical need for effective vaccines to manage outbreaks and protect populations.

The Ebola virus vaccine market is an important part of global efforts to prevent and control future outbreaks of the illness. Collaborations among governments, pharmaceutical corporations, academic institutions, and non-profit groups are driving Ebola virus vaccine development, manufacturing capacity and global distribution. Market challenges include assuring vaccine price and accessibility, particularly in low-income countries, tackling vaccination hesitancy and disinformation, and maintaining long-term manufacturing and supply networks.

What was the global Outbreaks of Ebola Virus Vaccine Market?

According to the National Library of Medicine, the outbreak occurred in the year 1976. It struck southern Sudan and the northern part of the Democratic Republic of Congo and lasted for about four months, lasting from June to September, with a mortality rate of 53% and 88.1%, respectively. The two viruses that were later identified and held accountable for the first outbreak were Sudan ebolavirus and Zaire ebolavirus.

The growth and development of the Ebola virus vaccine market. The most important requirement is to handle the public health crisis caused by Ebola epidemics. The destructive effects of Ebola virus disease (EVD) on human health, as well as its potential for broad transmission, highlight the need for effective preventive measures.

The expansion and development of the Ebola virus vaccine market, establishing it as an essential component of global health security efforts. The combination of scientific, financial, regulatory, and geopolitical forces emphasizes the strong drivers propelling.

What are the Challenges Faced by the Ebola Virus Vaccine Market?

The current demand for Ebola vaccinations is mostly driven by outbreak response efforts. Widespread vaccination programs have yet to be undertaken due to variables such as the unexpected nature of outbreaks and the concentration of illnesses in low and middle income countries with limited medical resources.

High costs for developing and manufacturing vaccinations are costly operations. This can result in high vaccine pricing, thereby limiting affordability and accessibility in resource-constrained areas most vulnerable to epidemics.

Logistical challenges include distributing and storing vaccines in remote places with little infrastructure. Maintaining the requisite cold chain conditions for these vaccinations along the supply chain adds a new level of complication.

Stringent regulatory licensing for Ebola virus vaccines might severely impede market expansion. Regulatory requirements can slow the launch of new vaccinations and prevent new businesses from entering the market. Increasing approval time and expenses for vaccine development and commercialization may restrict market growth. Small enterprises with limited resources may struggle to comply with tight laws, which require comprehensive clinical trials, safety evaluations, and manufacturing requirements. Regulatory barriers might impede the commercialization and availability of Ebola virus vaccines, hindering market growth.

Category-Wise Acumens

How the Vesicular Stomatitis Virus Platform has emerged in Ebola Virus Vaccine Market?

In the Ebola virus vaccine the vesicular stomatitis virus (rVSV) platform has emerged as a dominant force and is rapidly expanding. The rVSV platform makes use of a genetically modified vesicular stomatitis virus, with the surface glycoprotein replaced by that of the Ebola virus. In clinical trials, this platform showed encouraging findings, including high effectiveness and the potential to induce powerful immune responses against Ebola virus infection.

Accine platforms, such as animal adenovirus type 3 (ChAd3) and adenovirus serotype 26 (Ad26), are also making progress in the sector. ChAd3 and Ad26 vaccines use adenovirus vectors to transmit genetic material encoding Ebola virus antigens, thereby inducing an immune response. These systems have shown efficacy and safety characteristics in clinical trials and are being investigated as potential replacements or complementing vaccines to the rVSV platform.

The Ebola virus vaccine market the rVSV platform presently leading. The ChAd3 and Ad26 platforms are also rapidly expanding and offer intriguing options in the search for effective Ebola virus vaccines. Continued research and development across many vaccine platforms is critical to addressing the complex challenges posed by Ebola virus infection and ensuring the availability of viable vaccines for future outbreaks.

How the Hospitals & Government Suppliers contain the supreme for several reasons for in Ebola Virus Vaccine Market?

The supreme for several reasons for Ebola Virus Vaccine the Hospitals and Government Suppliers this route is dominant for numerous reasons. Ebola outbreaks typically occur in areas with limited access to retail pharmacies. Because of the vaccines particular storage requirements (cold chain maintenance) hospitals and government entities have the facility and competence to handle them properly. Finally, during outbreaks, governments frequently coordinate vaccination programs, making them key distributors.

The Ebola vaccine market is likely to be limited position but online pharmacies are a fast-increasing part of the pharmaceutical industry. The aforementioned cold chain requirements, combined with the fact that Ebola vaccines are typically utilized during outbreaks (rather than for normal injections), make online pharmacies an unsuitable alternative.

How Vaccines and Healthcare Industries are increasing in North America by Ebola Virus Vaccine Market?

The increasing development of vaccines and pharmaceuticals in the healthcare industry, as well as the presence of leading pharmaceutical companies in North America, the market in this region is expected to rise significantly throughout the forecast period.

North America, especially the United States, has a booming pharmaceutical industry distinguished by cutting-edge R&D infrastructure, modern manufacturing capabilities and a favourable regulatory framework. The region is home to several renowned pharmaceutical corporations, including Pfizer, Johnson & Johnson, Merck & Co., and Moderna, among others, which are constantly investing in breakthrough medication discovery and development projects.

North America is expected to benefit from rapid expansion in the healthcare business. The region's premier pharmaceutical businesses, combined with ongoing investments in R&D and technical innovation, will propel healthcare forward and contribute to the region's status as a global pharmaceutical powerhouse.

How the Ebola virus vaccine market Present in Asia-Pacific?

The Ebola virus vaccine market in the Asia Pacific is a complex environment with many elements influencing its development and accessibility. Historically, the region has had less direct exposure to Ebola outbreaks than regions such as Africa, but concerns about the virus's potential spread and the need for preparedness have motivated increased focus on vaccine development and deployment.

The Asia Pacific area is distinguished by country-specific variations in healthcare infrastructure and resources. While some countries have advanced healthcare systems and research capacities, others confront severe challenges such as limited budget, inadequate infrastructure, and a healthcare manpower shortage. These obstacles can stymie vaccine research efforts and restrict access to immunizations in impoverished communities.

Asia Pacific offers chances for innovation and collaboration in the Ebola virus vaccination industry. As the region's healthcare infrastructure and research capacity improve, there is an opportunity for increased investment in vaccine development and distribution. Furthermore, addressing health inequities and ensuring fair access to vaccines will be critical to effectively managing possible Ebola outbreaks throughout Asia Pacific.

Competitive Landscape

The Ebola virus vaccine market industry companies use numerous tactics such as collaborations, acquisitions, mergers, and partnerships to establish a global presence and remain competitive. Please note that the company profile section includes both commercially available drugs and those in clinical development.

The Ebola Virus Vaccine Market study report will provide valuable insight with an emphasis on the global market. The major players in the market include:

Sarepta Therapeutics

Mapp Biopharmaceutical

Regeneron Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Novavax, Inc.

GeoVax

Tekmira Pharmaceuticals

NewLink Genetics Corporation,

Bavarian Nordic

Merck & Co., Inc.

Johnson & Johnson.

Latest Developments

In October 2022, Merck & Co. will manufacture and give an investigational Sudan ebolavirus vaccine to a global non-profit organization's research program in Uganda, which is experiencing an outbreak.

In November 2021, the University of Oxford began phase one of its studies, evaluating the vaccine on human volunteers. In phase one of the studies, 26 participants aged 18 to 55 will get a single dose of the ChAdOx1 biEBOV Ebola vaccine at the university. They will subsequently be studied for six months, with the results expected in the second quarter of 2022.

In July 2020, Johnson & Johnson gained European Commission approval for an Ebola vaccine regimen for the prevention of Ebola Virus disease. The company's plan approval allows for collaboration with the World Health Organization (WHO) on vaccine pre-qualification, resulting in faster registration of its Ebola vaccine in African nations and a stronger market position.

1 INTRODUCTION OF GLOBAL EBOLA VIRUS VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL EBOLA VIRUS VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL EBOLA VIRUS VACCINE MARKET, BY VIRUS STRAIN

5.1 Overview
5.2 Recombinant Vesicular Stomatitis Virus
5.3 Chimpanzee Adeno Virus Type 3
5.4 Adeno Virus Serotype 26

6 GLOBAL EBOLA VIRUS VACCINE MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
6.2 Hospital & Retail Pharmacies
6.3 Online Pharmacies
6.4 Government suppliers
6.5 Others

7 GLOBAL EBOLA VIRUS VACCINE MARKET, BY END USER

7.1 Overview
7.2 Hospital
7.3 Homecare
7.4 Specialty Clinics
7.5 Ambulatory Surgical Centres
7.6 Others

8 GLOBAL EBOLA VIRUS VACCINE MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL EBOLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sarepta Therapeutics
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Mapp Biopharmaceutical
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Regeneron Pharmaceuticals, Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 GlaxoSmithKline plc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Novavax, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 GeoVax
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Tekmira Pharmaceuticals
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 NewLink Genetics Corporation
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bavarian Nordic
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Merck & Co., Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 KEY DEVELOPMENTS

11.1 Product Launches/Developments
11.2 Mergers and Acquisitions
11.3 Business Expansions
11.4 Partnerships and Collaborations

12 Appendix

12.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年伊波拉病毒疫苗市场（按病毒株、通路、最终用户和地区划分）

Ebola Virus Vaccine Market By Virus Strain, Distribution Channel, End User, & Region for 2026-2032

伊波拉病毒疫苗市场评估 - 2026-2032

全球伊波拉疫苗市场是什么样的？

伊波拉疫苗市场面临哪些挑战？

目录

第一章全球伊波拉病毒疫苗市场简介

第二章执行摘要

第三章：已验证的市场研究调查方法

第四章全球伊波拉疫苗市场展望

第五章全球伊波拉病毒疫苗市场（以病毒株）

第六章全球伊波拉病毒疫苗市场（按分销管道）

第七章全球伊波拉病毒疫苗市场（依最终用户）

第八章全球伊波拉病毒疫苗市场（按地区）

9. 全球伊波拉病毒疫苗市场竞争格局

第十章 公司简介

第十一章 重大进展

第十二章 附录

Ebola Virus Vaccine Market Valuation - 2026-2032